Recent Price Movement and Market Context
On 24 Nov 2025, Kopran's share price touched Rs.126.6, the lowest level recorded in the past year. This follows a two-day consecutive decline during which the stock has delivered a cumulative return of -5.52%. The day’s performance showed a drop of 1.71%, underperforming the Pharmaceuticals & Biotechnology sector by 1.68%. Kopran is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a sustained downward trend in its price momentum.
In contrast, the broader market has exhibited resilience. The Sensex opened 88.12 points higher and is trading at 85,455.79, up 0.26% on the day. The index is approaching its 52-week high of 85,801.70, just 0.4% away, and has recorded a 2.69% gain over the past three weeks. Mega-cap stocks are leading this positive momentum, with the Sensex trading above its 50-day moving average, which itself is positioned above the 200-day moving average, signalling a bullish market environment.
Just made the cut! This Mid Cap from the Heavy Electrical Equipment sector entered our elite Top 1% list recently. Discover it before the crowd catches on!
- - Top-rated across platform
- - Strong price momentum
- - Near-term growth potential
Long-Term Performance and Financial Indicators
Kopran’s one-year performance shows a return of -42.35%, a stark contrast to the Sensex’s 8.01% gain over the same period. The stock’s 52-week high was Rs.236.1, highlighting the extent of the decline. Over the last five years, the company’s operating profit has shown a negative compound annual growth rate of approximately -11.79%, reflecting subdued growth in core earnings.
Recent quarterly results have been unfavourable, with the company reporting negative outcomes for five consecutive quarters. The September 2025 quarter saw a net sales reduction of 22.2%, accompanied by a net loss after tax (PAT) of Rs. -9.92 crores, representing a fall of 234.4% compared to the previous period. The return on capital employed (ROCE) for the half-year stood at a low 5.38%, while the operating profit to interest coverage ratio was negative at -2.53 times, indicating challenges in covering interest expenses from operating earnings.
Shareholding and Market Perception
Despite Kopran’s market capitalisation, domestic mutual funds hold a minimal stake of just 0.01%. Given that domestic mutual funds typically conduct thorough research on companies, this limited exposure may reflect a cautious stance towards the stock’s current valuation and business outlook.
The stock has also underperformed the BSE500 index over the last three years, one year, and three months, underscoring a pattern of below-par returns relative to a broad market benchmark.
Balance Sheet and Valuation Metrics
Kopran maintains a relatively low average debt-to-equity ratio of 0.23 times, suggesting limited leverage on its balance sheet. The company’s ROCE of 4.7 and an enterprise value to capital employed ratio of 1.2 indicate an attractive valuation compared to peers’ historical averages. However, these valuation metrics have not translated into positive returns or earnings growth over the past year, during which profits declined by 66.7%.
Holding Kopran from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Key Challenges
The persistent decline in Kopran’s share price to a 52-week low reflects a combination of factors including sustained negative quarterly results, declining sales, and subdued profitability metrics. The stock’s performance contrasts sharply with the broader market’s upward trajectory, highlighting sector-specific and company-specific pressures. While the company’s low leverage and valuation metrics may be viewed as positives, these have not yet translated into improved financial outcomes or market performance.
Investors and market participants will note the stock’s position below all major moving averages and its underperformance relative to sector and market indices. The limited mutual fund holding further emphasises a cautious market stance towards Kopran at this juncture.
Market Outlook and Positioning
As of 24 Nov 2025, Kopran’s stock price at Rs.126.6 represents a significant retracement from its 52-week high of Rs.236.1. The stock’s trajectory over the past year and recent quarters indicates ongoing pressures within the Pharmaceuticals & Biotechnology sector and the company’s operational environment. The broader market’s positive momentum contrasts with Kopran’s challenges, underscoring the differentiated performance within the sector.
Overall, Kopran’s current market position reflects a complex interplay of financial results, valuation considerations, and market sentiment, culminating in the stock’s recent 52-week low.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
